Trials / Unknown
UnknownNCT01670162
On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)
On-label tReatment With Intravitreal Aflibercept Injection for Patients With Persistent Pigment Epithelial Detachments in Neovascular AMD.
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Tennessee Retina · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of intravitreal aflibercept injection in a population of neovascular AMD patients that have been previously treated with 2.0 mg ranibizumab for persistent PEDs.
Detailed description
A Phase 4 study to evaluate the efficacy and safety of intravitreal aflibercept injection in a population of neovascular AMD patients that have been previously treated with 2.0 mg ranibizumab for persistent PEDs (the ROLL study).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aflibercept | Intravitreal Injection 2mg/0.05mL Aflibercept |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2015-11-01
- Completion
- 2016-01-01
- First posted
- 2012-08-21
- Last updated
- 2014-10-29
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01670162. Inclusion in this directory is not an endorsement.